Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
CASI Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:CASI | Benzinga
CASI Pharmaceuticals Inc has a consensus price target of $8.67 based on the ratings of 3 analysts. The high is $12 issued by HC Wainwright & Co. on August 15, 2022. The low is $4 issued by HC Wainwright & Co. on April 9, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on April 9, 2025, May 15, 2024, and November 15, 2023, respectively. With an average price target of $7.33 between HC Wainwright & Co., there's an implied 309.68% upside for CASI Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
BTIG
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for CASI Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/09/2025 | Buy Now | 123.46% | HC Wainwright & Co. | Sean Lee68% | $6 → $4 | Maintains | Buy | Get Alert |
| 05/15/2024 | Buy Now | 235.2% | HC Wainwright & Co. | Sean Lee68% | $12 → $6 | Maintains | Buy | Get Alert |
| 11/15/2023 | Buy Now | 570.39% | HC Wainwright & Co. | Sean Lee68% | $10 → $12 | Maintains | Buy | Get Alert |
| 08/14/2023 | Buy Now | 458.66% | HC Wainwright & Co. | Sean Lee68% | → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/22/2023 | Buy Now | 458.66% | HC Wainwright & Co. | Sean Lee68% | → $10 | Reiterates | Buy → Buy | Get Alert |
| 11/16/2022 | Buy Now | 458.66% | BTIG | Justin Zelin40% | $21 → $10 | Maintains | Buy | Get Alert |
| 11/15/2022 | Buy Now | 458.66% | HC Wainwright & Co. | Sean Lee68% | $12 → $10 | Maintains | Buy | Get Alert |
| 08/15/2022 | Buy Now | 570.39% | HC Wainwright & Co. | Swayampakula Ramakanth51% | $3 → $12 | Maintains | Buy | Get Alert |
| 06/03/2022 | Buy Now | 1073.18% | BTIG | Justin Zelin40% | $4 → $21 | Maintains | Buy | Get Alert |
| 05/16/2022 | Buy Now | 67.6% | HC Wainwright & Co. | Sean Lee68% | $4 → $3 | Maintains | Buy | Get Alert |
FAQ
What is the target price for CASI Pharmaceuticals (CASI) stock?
The latest price target for CASI Pharmaceuticals (NASDAQ:CASI) was reported by HC Wainwright & Co. on April 9, 2025. The analyst firm set a price target for $4.00 expecting CASI to rise to within 12 months (a possible 123.46% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for CASI Pharmaceuticals (CASI)?
The latest analyst rating for CASI Pharmaceuticals (NASDAQ:CASI) was provided by HC Wainwright & Co., and CASI Pharmaceuticals maintained their buy rating.
When was the last upgrade for CASI Pharmaceuticals (CASI)?
There is no last upgrade for CASI Pharmaceuticals
When was the last downgrade for CASI Pharmaceuticals (CASI)?
There is no last downgrade for CASI Pharmaceuticals.
When is the next analyst rating going to be posted or updated for CASI Pharmaceuticals (CASI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CASI Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CASI Pharmaceuticals was filed on April 9, 2025 so you should expect the next rating to be made available sometime around April 9, 2026.
Is the Analyst Rating CASI Pharmaceuticals (CASI) correct?
While ratings are subjective and will change, the latest CASI Pharmaceuticals (CASI) rating was a maintained with a price target of $6.00 to $4.00. The current price CASI Pharmaceuticals (CASI) is trading at is $1.79, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
